News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
621,221 Results
Type
Article (52071)
Company Profile (131)
Press Release (569006)
Multimedia
Podcasts (169)
Webinars (22)
Section
Business (160693)
Career Advice (2552)
Deals (30074)
Drug Delivery (167)
Drug Development (75873)
Employer Resources (163)
FDA (16649)
Job Trends (13152)
News (291317)
Policy (32133)
Tag
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (3)
2027 Genetown Standard (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2666)
Academic (1)
Accelerated approval (54)
Adcomms (40)
Allergies (169)
Alliances (40164)
ALS (215)
Alzheimer's disease (1955)
Antibody-drug conjugate (ADC) (485)
Approvals (16925)
Artificial intelligence (674)
Autoimmune disease (315)
Automation (52)
Bankruptcy (328)
Best Places to Work (10088)
BIOSECURE Act (23)
Biosimilars (225)
Biotechnology (78)
Bladder cancer (206)
Brain cancer (74)
Breast cancer (751)
Cancer (5903)
Cardiovascular disease (517)
Career advice (2168)
Career pathing (49)
CAR-T (322)
CDC (76)
Celiac Disease (2)
Cell therapy (917)
Cervical cancer (48)
Clinical research (65959)
Collaboration (1943)
Company closure (7)
Compensation (1417)
Complete response letters (102)
COVID-19 (2861)
CRISPR (109)
C-suite (1104)
Cystic fibrosis (158)
Data (7985)
Decentralized trials (3)
Denatured (38)
Depression (184)
Dermatology (90)
Diabetes (611)
Diagnostics (6246)
Digital health (49)
Diversity (7)
Diversity, equity & inclusion (43)
Drug discovery (307)
Drug pricing (239)
Drug shortages (36)
Duchenne muscular dystrophy (301)
Earnings (68942)
Editorial (78)
Employer branding (20)
Employer resources (145)
Events (94486)
Executive appointments (1037)
FDA (20458)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (18)
Frontotemporal dementia (35)
Funding (1614)
Gene editing (242)
Generative AI (58)
Gene therapy (785)
GLP-1 (1204)
Government (4799)
Grass and pollen (8)
Guidances (408)
Healthcare (17083)
HIV (83)
Huntington's disease (61)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (106)
Immunology and inflammation (341)
Immuno-oncology (100)
Indications (186)
Infectious disease (3220)
Inflammatory bowel disease (221)
Inflation Reduction Act (15)
Influenza (131)
Intellectual property (291)
Interviews (471)
IPO (14840)
IRA (58)
Job creations (3323)
Job search strategy (1767)
JPM (69)
Kidney cancer (21)
Labor market (104)
Layoffs (647)
Leadership (51)
Legal (7465)
Liver cancer (105)
Longevity (30)
Lung cancer (778)
Lymphoma (428)
Machine learning (58)
Management (54)
Manufacturing (1026)
MASH (220)
Medical device (12504)
Medtech (12620)
Mergers & acquisitions (16434)
Metabolic disorders (1665)
mRNA (241)
Multiple sclerosis (189)
NASH (24)
Neurodegenerative disease (475)
Neuropsychiatric disorders (122)
Neuroscience (3555)
Neurotech (2)
NextGen: Class of 2026 (5616)
Non-profit (3898)
Now hiring (73)
Obesity (806)
Opinion (321)
Ovarian cancer (220)
Pain (258)
Pancreatic cancer (310)
Parkinson's disease (384)
Partnered (29)
Patents (603)
Patient recruitment (673)
Peanut (59)
People (49960)
Pharmaceutical (37)
Pharmacy benefit managers (36)
Phase 1 (19956)
Phase 2 (28765)
Phase 3 (22653)
Pipeline (8829)
Policy (385)
Postmarket research (2565)
Preclinical (8563)
Press Release (39)
Prostate cancer (318)
Psychedelics (66)
Radiopharmaceuticals (319)
Rare diseases (1173)
Real estate (4703)
Recruiting (66)
Regulatory (25560)
Reports (48)
Research institute (2344)
Resumes & cover letters (423)
Rett syndrome (40)
RNA editing (23)
RSV (93)
Schizophrenia (191)
Series A (277)
Series B (199)
Service/supplier (8)
Sickle cell disease (116)
Special edition (30)
Spinal muscular atrophy (165)
Sponsored (53)
Startups (3109)
State (1)
Stomach cancer (21)
Supply chain (129)
Tariffs (104)
The Weekly (129)
Vaccines (1221)
Venture capital (122)
Weight loss (563)
Women's health (112)
Worklife (24)
Date
Today (34)
Last 7 days (565)
Last 30 days (3212)
Last 365 days (29380)
2026 (13283)
2025 (29509)
2024 (33103)
2023 (37054)
2022 (47458)
2021 (51364)
2020 (48936)
2019 (40452)
2018 (30599)
2017 (29968)
2016 (28601)
2015 (31933)
2014 (24981)
2013 (20501)
2012 (21994)
2011 (22433)
2010 (20479)
Location
Africa (754)
Alabama (79)
Alaska (6)
Arizona (283)
Arkansas (13)
Asia (35649)
Australia (6398)
California (12910)
Canada (3207)
China (1238)
Colorado (510)
Connecticut (572)
Delaware (383)
Europe (87223)
Florida (1945)
Georgia (398)
Hawaii (4)
Idaho (50)
Illinois (995)
India (86)
Indiana (573)
Iowa (24)
Japan (541)
Kansas (119)
Kentucky (39)
Louisiana (38)
Maine (81)
Maryland (1566)
Massachusetts (9259)
Michigan (315)
Minnesota (676)
Mississippi (5)
Missouri (135)
Montana (19)
Nebraska (26)
Nevada (136)
New Hampshire (80)
New Jersey (3432)
New Mexico (19)
New York (3368)
North Carolina (1660)
North Dakota (9)
Northern California (6572)
Ohio (363)
Oklahoma (19)
Oregon (38)
Pennsylvania (2484)
Puerto Rico (26)
Rhode Island (35)
South America (1119)
South Carolina (84)
South Dakota (2)
Southern California (5090)
Tennessee (190)
Texas (1994)
United States (45154)
Utah (375)
Virginia (325)
Washington D.C. (76)
Washington State (1016)
West Virginia (4)
Wisconsin (131)
Wyoming (1)
621,221 Results for "alzheimer s association".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Approvals
Axsome wins first non-antipsychotic FDA approval for Alzheimer’s agitation
Alzheimer’s disease agitation could mean peak sales of over $2.1 billion for Axsome’s Auvelity, according to analysts at William Blair.
May 1, 2026
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy
The FDA’s extension will give reviewers more time to review a major amendment to Biogen and Eisai’s application for a subcutaneous induction formulation of Alzheimer’s therapy Leqembi. The new target action date is on Aug. 24.
May 8, 2026
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Biogen ready to catch Alzheimer’s patients transitioning off Lilly’s Kisunla
Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer’s market as patients end their 18-month course of Lilly’s product.
April 29, 2026
·
3 min read
·
Annalee Armstrong
Alzheimer’s disease
Biogen’s Much Anticipated Tau Readout in Alzheimer’s Will Spur More Questions
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market.
February 9, 2026
·
4 min read
·
Annalee Armstrong
Drug Development
Biogen’s Alzheimer’s results bolster tau theory—and Denali’s next gen candidate
If Biogen has shown that tau can impact cognition, Denali’s technology—validated with an FDA approval in Hunter syndrome—could ensure the medicine gets where it needs to be for the greatest therapeutic impact, analysts said.
May 15, 2026
·
3 min read
·
Annalee Armstrong
Press Releases
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
April 30, 2026
·
21 min read
Alzheimer’s disease
In Novo’s GLP-1 Failure, Alzheimer’s Space Spies a Combination Opportunity
Despite the definitive failure of Novo Nordisk’s semaglutide in Alzheimer’s, biotech executives, analysts and other industry experts see potential in more testing of GLP-1s for the neurodegenerative disease, particularly in a combination approach.
January 2, 2026
·
5 min read
·
Annalee Armstrong
Alzheimer’s disease
I Remember Aduhelm. The Return of Roche in Alzheimer’s Is a Turning Point
After covering the Alzheimer’s space through every high and low,
BioSpace
’s Annalee Armstrong welcomes back Roche for the 2026 Alzheimer’s Renaissance.
December 2, 2025
·
2 min read
·
Annalee Armstrong
Press Releases
Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer’s Association International Conferences
March 10, 2026
·
8 min read
Earnings
BMS positions Cobenfy as safer alternative ahead of pivotal Alzheimer’s psychosis readout
After delaying a late-stage readout last year due to “irregularities” at certain study sites, pivotal data for Bristol Myers Squibb’s Cobenfy appear set to arrive later this year.
April 30, 2026
·
2 min read
·
Tristan Manalac
1 of 62,123
Next
